[1] KAPLAN G G, NG S C. Understanding and preventing the global increase of inflammatory bowel disease[J]. Gastroenterol, 2017,152(2):313-321. [2] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018 年,北京)[J]. 中华消化杂志, 2018,38(5):292-311. [3] RUNGOE C, BASIT S, RANTHE M F, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study[J]. Gut, 2013,62(5):689-694. [4] LIBBY P. Inflammation in atherosclerosis[J]. Nature, 2002,420(6917):868-874. [5] SAPPATI B R, PUTKA B S, MULLEN K D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease[J]. J Clin Lipidol, 2010,4(6):478-482. [6] ROMANATO G, SCARPA M, ANGRIMAN I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2009,29(3):298-307. [7] KOUTROUMPAKIS E, RAMOS-RIVERS C, REGUEIRO M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease[J]. Dig Dis Sci, 2016,61(3):865-871. [8] 贾喻, 王娟, 刘醒醒, 等. 溃疡性结肠炎患者的血脂异常及其临床意义[J]. 江苏医药, 2016,42 (11):1241-1243. [9] ZENG Z, ZHU Z, YANG Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province, China: a prospective population-based study[J]. J Gastroenterol Hepatol, 2013,28(7):1148-1153. [10] BORBA E F, CARVALHO J F, BONFA E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus[J]. Clin Dev Immunol, 2006,13(2-4):203-208. [11] BECKER S A, MCCLAVE S A. Lipid profiles in Crohn's disease patients with and without ileal resection[J]. Am J Gastroenterol, 1996,91(11):2452. [12] 张俊清. 探寻东西方2型糖尿病的差异——从现象到本质的思考[J]. 中国糖尿病杂志, 2016,24 (10):955-960. [13] 中国炎症性肠病协作组, 王玉芳, 欧阳钦. 3100例溃疡性结肠炎住院病例回顾分析[J]. 中华消化杂志, 2006,26 (6):368-372. [14] 潘丹峰, 苍玉珍. 应用膳食平衡指数评价溃疡性结肠炎患者膳食质量及营养状况[J]. 广州医药, 2018,49(4):34-38. [15] 张雷, 鞠大闯, 刘庭惠, 等. 复方纳米银抗菌水凝胶对溃疡性结肠炎大鼠肠道屏障功能的影响[J]. 现代医院, 2016,16(5):644-646, 649. [16] KOHAN A B. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease[J]. Curr Opin Endocrinol Diabetes Obes, 2015,22(2):119-125. [17] KONTUSH A. HDL-mediated mechanisms of protection in cardiovascular disease[J]. Cardiovasc Res, 2014,103(3):341-349. [18] ZeWINGER S, KLEBER M E, TRAGANTE V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study[J]. Lancet Diabetes Endocrinol, 2017,5(7):534-543. |